|
1
|
Fried MW, Shiffman ML, Reddy KR, Smith C,
Marinos G, Gonçales FL Jr, Häussinger D, Diago M, Carosi G,
Dhumeaux D, et al: Peginterferon alfa-2a plus ribavirin for chronic
hepatitis C virus infection. N Engl J Med. 347:975–982. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hadziyannis SJ, Sette H Jr, Morgan TR,
Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H Jr,
Bernstein D, Rizzetto M, et al: Peginterferon-alpha2a and ribavirin
combination therapy in chronic hepatitis C: A randomized study of
treatment duration and ribavirin dose. Ann Intern Med. 140:346–355.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang M, Jiang YF, Xiao XQ, Liu SF, Peng
ML, Liu D and Gong GZ: Dynamic changes in PD-1, TLR3, and TLR4
surface expression on peripheral blood mononuclear cells in chronic
hepatitis C patients undergoing PEG-IFNalpha-2a plus ribavirin
combination therapy. Zhonghua Gan Zang Bing Za Zhi. 21:196–201.
2013.(In Chinese). PubMed/NCBI
|
|
4
|
Akira S, Uematsu S and Takeuchi O:
Pathogen recognition and innate immunity. Cell. 124:783–801. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Machida K, Tsukamoto H, Mkrtchyan H, Duan
L, Dynnyk A, Liu HM, Asahina K, Govindarajan S, Ray R, Ou JH, et
al: Toll-like receptor 4 mediates synergism between alcohol and HCV
in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl
Acad Sci USA. 106:1548–1553. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tedgui A and Mallat Z: Cytokines in
atherosclerosis: Pathogenic and regulatory pathways. Physiol Rev.
86:515–581. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sahin H, Borkham-Kamphorst E, do O NT,
Berres ML, Kaldenbach M, Schmitz P, Weiskirchen R, Liedtke C,
Streetz KL, Maedler K, et al: Proapoptotic effects of the
chemokine, CXCL 10 are mediated by the noncognate receptor TLR4 in
hepatocytes. Hepatology. 57:797–805. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chinese Liver Disease Association, .
Chinese Infectious and Parasitic Diseases Association: The strategy
for prevention and therapy of viral hepatitis C. Chin J Clinic
Hepatol. 12:194–198. 2004.
|
|
9
|
Zeremski M, Dimova R, Brown Q, Jacobson
IM, Markatou M and Talal AH: Peripheral CXCR3-associated chemokines
as biomarkers of fibrosis in chronic hepatitis C virus infection. J
Infect Dis. 200:1774–1780. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cui Y and Jia J: Update on epidemiology of
hepatitis B and C in China. J Gastroenterol Hepatol. 28 Suppl
1:S7–S10. 2013. View Article : Google Scholar
|
|
11
|
Gruener NH, Lechner F, Jung MC, Diepolder
H, Gerlach T, Lauer G, Walker B, Sullivan J, Phillips R, Pape GR
and Klenerman P: Sustained dysfunction of antiviral CD8+ T
lymphocytes after infection with hepatitis C virus. J Virol.
75:5550–5558. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wedemeyer H, He XS, Nascimbeni M, Davis
AR, Greenberg HB, Hoofnagle JH, Liang TJ, Alter H and Rehermann B:
Impaired effector function of hepatitis C virus2specific CD8+ T
cells in chronic hepatitis C virus infection. J Immunol.
169:3447–3458. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Greenwald RJ, Freeman GH and Sharpe AH:
The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Nurieva R, Thomas S, Nguyen T,
Martin-Orozco N, Wang Y, Kaja MK, Yu XZ and Dong C: T-cell
tolerance or function is determined by combinatorial costimulatory
signals. EMBO J. 25:2623–2633. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Beutler B: Inferences, questions and
possibilities in toll-like receptor signalling. Nature.
430:257–263. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Machida K, Cheng KT, Sung VM, Levine AM,
Foung S and Lai MM: Hepatitis C virus induces toll-like receptor 4
expression, leading to enhanced production of beta interferon and
interleukin-6. J Virol. 80:866–874. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dolganiuc A, Norkina O, Kodys K, Catalano
D, Bakis G, Marshall C, Mandrekar P and Szabo G: Viral and host
factors induce macrophage activation and loss of toll-like receptor
tolerance in chronic HCV infection. Gastroenterology.
133:1627–1636. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Guo J and Friedman SL: Toll-like receptor
4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis
Tissue Repair. 3:212010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Q and Wang ZH: The changes of TLR4
expression and TNF-a secretion in BV2 cells after handled with HCV
positive serum. Courrent Immunlolgy. 31:219–222. 2011.(In
Chinese).
|
|
20
|
Wen M, Xiao XQ and Gong GZ: Hepatitis C
virus NS5A protein stimulates TLR4 expression. Chin J Clin Hepatol.
27:49–52. 2011.
|
|
21
|
Andreakos E, Foxwell B and Feldmann M: Is
targeting toll-like receptors and their signaling pathway a useful
therapeutic approach to modulating cytokine-driven inflammation?
Immunol Rev. 202:250–265. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Devaraj S and Jialal I: Increased
secretion of IP-10 from monocytes under hyperglycemia is via the
TLR2 and TLR4 pathway. Cytokine. 47:6–10. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Mihm S, Schweyer S and Ramadori G:
Expression of the chemokine IP-10 correlates with the accumulation
of hepatic IFN-gamm a and IL-18mRNA in chronic hepatitis C but not
in hepatitis B. J Med Virol. 70:562–570. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Fiorentino DF, Bond MW and Mosmann TR: Two
types of mouse T helper cells. IV. Th2 clones secrete a factor that
inhibits cytokine production by Th1 clones. J Exp Med.
170:2081–2095. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Antonelli A, Ferrari SM, Giuggioli D,
Ferrannini E, Ferri C and Fallahi P: Chemokine (C-X-C motif) ligand
(CXCL)10 in autoimmune diseases. Autoimmun Rev. 13:272–280. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Larrubia JR, Benito-Martínez S, Calvino M,
Sanz-de-Villalobos E and Parra-Cid T: Role of chemokines and their
receptors in viral persistence and liver damage during chronic
hepatitis C virus infection. World J Gastroenterol. 14:7149–7159.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zeremski M, Petrovic LM, Chiriboga L,
Brown QB, Yee HT, Kinkhabwala M, Jacobson IM, Dimova R, Markatou M
and Talal AH: Intrahepatic levels of CXCR3-associated chemokines
correlate with liver inflammation and fibrosis in chronic hepatitis
C. Hepatology. 48:1440–1450. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Harvey CE, Post JJ, Palladinetti P,
Freeman AJ, Ffrench RA, Kumar RK, Marinos G and Lloyd AR:
Expression of the chemokine IP-10 (CXCL10) by hepatocytes in
chronic hepatitis C virus infection correlates with histological
severity and lobular inflammation. J Leukoc Biol. 74:360–369. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Narumi S, Tominaga Y, Tamaru M, Shimai S,
Okumura H, Nishioji K, Itoh Y and Okanoue T: Expression of
IFN-inducible protein-10 in chronic hepatitis. J Immunol.
158:5536–5544. 1997.PubMed/NCBI
|
|
30
|
Shields PL, Morland CM, Salmon M, Qin S,
Hubscher SG and Adams DH: Chemokine and chemokine receptor
interactions provide a mechanism for selective T cell recruitment
to specific liver compartments within hepatitis C-infected liver. J
Immunol. 163:6236–6243. 1999.PubMed/NCBI
|
|
31
|
Romero AI, Lagging M, Westin J, Dhillon
AP, Dustin LB, Pawlotsky JM, Neumann AU, Ferrari C, Missale G,
Haagmans BL, et al: Interferon (IFN)-gamma-inducible protein-10:
Association with histological results, viral kinetics, and outcome
during treatment with pegylated IFN-alpha 2a and ribavirin for
chronic hepatitis C virus infection. J Infect Dis. 194:895–903.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Butera D, Marukian S, Iwamaye AE,
Hembrador E, Chambers TJ, Di Bisceglie AM, Charles ED, Talal AH,
Jacobson IM, Rice CM and Dustin LB: Plasma chemokine levels
correlate with the outcome of antiviral therapy in patients with
hepatitis C. Blood. 106:1175–1182. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Diago M, Castellano G, García-Samaniego J,
Pérez C, Fernández I, Romero M, Iacono OL and García-Monzón C:
Association of pretreatment serum interferon gamma inducible
protein 10 levels with sustained virological response to
peginterferon plus ribavirin therapy in genotype 1 infected
patients with chronic hepatitis C. Gut. 55:374–379. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Darling JM, Aerssens J, Fanning G,
McHutchison JG, Goldstein DB, Thompson AJ, Shianna KV, Afdhal NH,
Hudson ML, Howell CD, et al: Quantitation of pretreatment serum
interferon-γ-inducible protein-10 improves the predictive value of
an IL28B gene polymorphism for hepatitis C treatment response.
Hepatology. 53:14–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
